KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Outcome for Outcome Of Board Meeting
Disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201515-03-2023
15-03-2023
KILITCH DRUGS (INDIA) LTD. - 524500 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Financial Results for the quarter ended 31st December, 202215-02-2023
KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Outcome for OUTCOME OF BOARD MEETING
Approval of quarterly results and reappointment of independent director14-02-2023
KILITCH DRUGS (INDIA) LTD. - 524500 - Financial Results For The Quarter Ended 31St December, 2022
Financial Results for the quarter ended 31st December, 202214-02-2023
KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Considering The Financial Results For The Quarter Ended 31St December, 2022
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday, 14th February, 2023 inter-alia to consider and approve the Standalone and Consolidated un-audited Financial Results of the Company for the quarter ended 31st December, 2022.03-02-2023
KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018, enclosed herewith is the Certificate received from Link Intime India Private Limited, the Registrar and Share Transfer Agent of the Company for the quarter ended 31st December, 2022.12-01-2023
KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
In continuation of disclosure dated 31st December, 2022 submitted pursuant to provisions of regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details of the Kilitch Estro Biotech equity, foreign subsidiary of the company shares of which are being acquired is enclosed03-01-2023
KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Pursuant to provisions of regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Company has made additional investment of USD 2,68,000 to acquire equity shares of Kilitch Estro Biotech PLC, foreign subsidiary of the Company to meet working capital requirement of the Company.31-12-2022
KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with Code of Prohibition of Insider Trading of the Company, the Trading Windows for dealing in Securities of the Company will remain closed for all the Designated Persons of the Company and their immediate relatives with effect from Sunday, 1st January, 2023 till the expiry of 48 hours after the declaration of Financial Results of the Company for the quarter ended 31st December, 2022.30-12-2022